Related to Radius Raises $26.75M for Phase III Osteoporosis Trial

• Novartis' Osteoporosis Drug Gets FDA Okay for Preventing Postmenopausal Osteoporosis
  
• EU Sanctions Novartis Drug for Steroid-Induced Osteoporosis
  
• Galapagos Receives $3.57M for Reaching Milestone in Osteoporosis Collaboration with Lilly
  
• GSK to Pay $120M for Commercial Rights to Amgen’s Lead mAb
  
• Scientists Reveal Immune System's Role in Bone Loss
  
• Scientists Find New Link between Osteoporosis and Celiac Disease
  
• Amgen Set Back with Prolia Approval in Postmenopausal Osteoporosis
  
• Interleukin Genetics Launches Bone Health Genetic Test
  
• Amgen Wins Approval for Osteoporosis Therapy for Postmenopausal Women
  
• NIH Gives Out $1.3M in Grants to Support Biomedical Research in Space
  
• FDA Filing for Tarsa’s Oral Calcitonin Projected by Year-End Following Positive Phase III Data
  
• Nycomed to Market Roche’s Osteoporosis Treatment in Asia Pacific
  
• Unigene and GSK Broaden Deal in Anticipation of Phase III Trial in Postmenopausal Osteoporosis
  
• Unigene and Nordic Set Up Joint Venture to Develop Three Peptide Therapeutics
  
• AKP Pays Zosano $7.5M as Part of Asian Agreement for Transdermal Parathyroid Hormone Patch
  
• Unigene Regains Oral rPTH Osteoporosis Candidate from GSK
  
• Tarsa Raises $28M to Take Oral Calcitonin Through Regulatory Approval in the U.S.
  
• NPS Buys Teduglutide, PTH 1-84 Rights from Takeda for Up to $80M
  
• Cash-Strapped Unigene Gets $1M Boost from Nordic
  
• Radius Raises $91M for Pivotal Osteoporosis Trial and Inks Transdermal Patch Deal with 3M